Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jingning Granules
- Development stage
- Preclinical
- Lead developer
- Kangrentang
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Jingning Granules (静宁颗粒) is a traditional Chinese medicine (TCM) formulation developed for the treatment of pediatric attention deficit hyperactivity disorder (ADHD). It is used as an adjunct to cognitive training and aims to provide clinical benefit in managing symptoms of ADHD in children. The granule formulation is based on TCM principles, but the precise herbal composition and mechanism of action are not fully detailed in public sources. Preclinical studies have also explored related formulations for effects on neuroendocrine function and neurotransmitter modulation, suggesting possible central nervous system activity[1][4].
- Brand names
- Jingning Granules
- Other names
- 静宁颗粒
02
Targets
DRD1 (Dopamine D1 Receptor)DRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on Jingning Granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jingning Granules.